The Asia Pacific Contrast Media Market would witness market growth of 4.9% CAGR during the forecast period (2019-2025).
The Asia Pacific Contrast Media Market is growing at a fast pace. The ophthalmic laser market is expected to see remarkable growth in the forecast period due to an increase in the number of aging populations, increased research and development activities in the field of imaging modalities, demand image-guided techniques, and an increasing incidence of chronic diseases. Nonetheless, adverse reactions of contrast media on the body and the enormous costs involved hinder the market growth. Due to the huge population, China and India are likely to witness an increase in demand.
For MRIs, contrast agents minimize nuclei relaxation times within the tissues of the body to modify the contrast in an image. Gadolinium is a contrast agent used in MRI. The metal has seven unpaired electrons in the 3 + oxidation state, which helps water to relax quickly around the contrast agent, thereby improving the quality of the MRI scan. MRI contrast agents are commonly used to enhance the disparity in the contrast between normal and abnormal tissues. MRI contrast agents can be administered either orally or intravenously.
Based on Product Type, the market is segmented into Iodinated, Barium-based, Gadolinium-based and Microbubble. Based on Application, the market is segmented into Neurological disorders, Cancer, Cardiovascular disorders, Gastrointestinal disorders, Nephrological disorders, Musculoskeletal disorders and Other Applications. Based on Modality, the market is segmented into X-ray/CT, MRI and Ultrasound. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.
Scope of the Study
By Product Type
- Neurological disorders
- Cardiovascular disorders
- Gastrointestinal disorders
- Nephrological disorders
- Musculoskeletal disorders
- Other Applications
- South Korea
- Rest of Asia Pacific
- Bayer AG
- General Electric (GE) Co. (GE Healthcare)
- The Guerbet Group
- Lantheus Holdings, Inc.
- Bracco S.p.A.
- Trivitron Healthcare Pvt. Ltd.
- Nano Therapeutics Pvt. Ltd.
- Magnus Health, LLC (Veracross LLC)
- Imax Diagnostic Imaging Limited
- Daiichi Sankyo Company, Limited
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free